Literature DB >> 11558696

Is technological change in medicine worth it?

D M Cutler1, M McClellan.   

Abstract

Medical technology is valuable if the benefits of medical advances exceed the costs. We analyze technological change in five conditions to determine if this is so. In four of the conditions--heart attacks, low-birthweight infants, depression, and cataracts--the estimated benefit of technological change is much greater than the cost. In the fifth condition, breast cancer, costs and benefits are about of equal magnitude. We conclude that medical spending as a whole is worth the increased cost of care. This has many implications for public policy.

Entities:  

Mesh:

Year:  2001        PMID: 11558696     DOI: 10.1377/hlthaff.20.5.11

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  96 in total

1.  Returns on research and development for 1990s new drug introductions.

Authors:  Henry Grabowski; John Vernon; Joseph A DiMasi
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

2.  Prevalence of comorbid conditions with aging among patients with diabetes and cardiovascular disease.

Authors:  James W Davis; Richard Chung; Deborah T Juarez
Journal:  Hawaii Med J       Date:  2011-10

3.  Medical expenditures during the last year of life: findings from the 1992-1996 Medicare current beneficiary survey.

Authors:  Donald R Hoover; Stephen Crystal; Rizie Kumar; Usha Sambamoorthi; Joel C Cantor
Journal:  Health Serv Res       Date:  2002-12       Impact factor: 3.402

4.  The aging population and its impact on the surgery workforce.

Authors:  David A Etzioni; Jerome H Liu; Melinda A Maggard; Clifford Y Ko
Journal:  Ann Surg       Date:  2003-08       Impact factor: 12.969

5.  The alignment and blending of payment incentives within physician organizations.

Authors:  James C Robinson; Stephen M Shortell; Rui Li; Lawrence P Casalino; Thomas Rundall
Journal:  Health Serv Res       Date:  2004-10       Impact factor: 3.402

6.  The role of funding and policies on innovation in cancer drug development.

Authors:  P Kanavos; R Sullivan; G Lewison; W Schurer; S Eckhouse; Z Vlachopioti
Journal:  Ecancermedicalscience       Date:  2010-02-03

7.  Endogenous technological change in medicine and its impact on healthcare costs: evidence from the pharmaceutical market in Taiwan.

Authors:  Chee-Ruey Hsieh; Ya-Ming Liu; Chia-Lin Chang
Journal:  Eur J Health Econ       Date:  2011-12-27

8.  Spending more money, saving more lives? The relationship between avoidable mortality and healthcare spending in 14 countries.

Authors:  Richard Heijink; Xander Koolman; Gert P Westert
Journal:  Eur J Health Econ       Date:  2012-06-08

9.  Comparing the cost effectiveness of risperidone and olanzapine in the treatment of schizophrenia using the net-benefit regression approach.

Authors:  Annemieke De Ridder; Diana De Graeve
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

Review 10.  What works and what doesn't work well in the US healthcare system.

Authors:  Harold S Luft
Journal:  Pharmacoeconomics       Date:  2006-12       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.